Serina Therapeutics, Inc.
SER- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001708599
In the last 90 days, Serina Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.73M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Serina Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $2.03K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$2.03K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Serina Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Simon Farrell | Director | – | Jul 23, 2026 | 1 |
| Brannan Stephen K. | Director | 1,000 | Jul 9, 2026 | 3 |
| Wilson Karen J | Director | 10,100 | Jun 22, 2026 | 4 |
| Bailey Gregory | Director | 8,564,382 | Jun 22, 2026 | 3 |
| Venkatesan Jay | Director | 231,705Indirect | Jun 22, 2026 | 3 |
| Marshall Richard Peter | Director | 12,183 | Jun 22, 2026 | 3 |
| Ledger Steven A | Chief Executive Officer | 10,100 | May 27, 2026 | 3 |
| Curhan Gregory S | Chief Financial Officer | – | May 26, 2026 | 1 |
| Moreadith Randall | Chief Scientific Officer | 0 | May 26, 2026 | 27 |
| Tenjarla Srini | SVP, CMC & Formulation | – | May 26, 2026 | 2 |
| Gill Simba | Director | – | Feb 17, 2026 | 1 |
| Juvenescence Ltd | 10% Owner | 3,267,188Indirect | Feb 3, 2025 | 0 |
| Mintz Steven | Director | 17,443Indirect | Sep 16, 2024 | 0 |
| Harris J Milton | Director | – | Apr 3, 2024 | 0 |
| Gross Remy | Director | – | Apr 3, 2024 | 0 |
| West Michael D | Chief Executive Officer | 41,982 | Mar 14, 2023 | 0 |
| Hackett Joanne M. | Director | – | Feb 4, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 20, 2026 (view filing)2:20 PM ET | Mar 19 | 1 day | Moreadith RandallChief Scientific Officer | SSale | −39.0K | $2.50 | −$97.5K | −100.0%0 after | 10b5-1 |
| Mar 24, 2026 (view filing)7:24 PM ET | Mar 23 | 1 day | Moreadith RandallChief Scientific Officer | SSale | −6.50K | $2.86 | −$18.6K | −100.0%0 after | 10b5-1 |
| May 22, 2026 (view filing) | May 19 | 3 daysLate | Marshall Richard PeterDirector | PPurchase | +12.2K | $1.65 | +$20.1K | New position12.2K after | |
| May 26, 2026 (view filing) | May 21-22 | 5 days | Wilson Karen JDirector | PPurchase | +20.0K | $1.85 | +$37.0K | New position20.0K after | 2 lots |
| Jun 15, 2026 (view filing) | Jun 11-12 | 4 days | Wilson Karen JDirector | PPurchase | +10.1K | $1.76 | +$17.8K | New position10.1K after | 2 lots |
| Jun 22, 2026 (view filing) | May 22 | 31 daysLate | Venkatesan JayDirector | PPurchase | +589 | $1.78 | +$1.05K | New position589 after | |
| Jul 9, 2026 (view filing)12:05 PM ET | Jul 7 | 2 days | Brannan Stephen K.Director | PPurchase | +1.00K | $2.03 | +$2.03K | New position1.00K after |